Midostaurin – a staurosporine analog with a multikinase inhibitory activity against KIT, PDGFR, PKC, VEGF, and FLT3 (amongst others) – was the first FLT3 inhibitor to be approved for frontline therapy in AML patients with FLT3 mutations and fit for intensive chemotherapy [67]. This evidence concerns the gene FLT3 and acute myeloid leukemia.